Stem definition | Drug id | CAS RN |
---|---|---|
5521 | 79338-84-4 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
May 23, 2022 | FDA | DERMAVANT SCIENCES INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Folliculitis | 101.29 | 91.57 | 25 | 133 | 70292 | 63418572 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Folliculitis | 275.34 | 116.85 | 41 | 120 | 4525 | 34952245 |
None
None
Source | Code | Description |
---|---|---|
FDA EPC | N0000194018 | Aryl Hydrocarbon Receptor Agonist |
FDA MoA | N0000194019 | Aryl Hydrocarbon Receptor Agonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Plaque psoriasis | indication | 200965009 |
None
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
1% | VTAMA | DERMAVANT SCI | N215272 | May 23, 2022 | RX | CREAM | TOPICAL | 10426743 | May 19, 2036 | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS |
1% | VTAMA | DERMAVANT SCI | N215272 | May 23, 2022 | RX | CREAM | TOPICAL | 11612573 | May 19, 2036 | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS |
1% | VTAMA | DERMAVANT SCI | N215272 | May 23, 2022 | RX | CREAM | TOPICAL | 11590088 | Nov. 13, 2039 | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1% | VTAMA | DERMAVANT SCI | N215272 | May 23, 2022 | RX | CREAM | TOPICAL | May 23, 2027 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Aryl hydrocarbon receptor | Transcription factor | AGONIST | EC50 | 9.80 | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
CHEMBL259571 | ChEMBL_ID |
C571829 | MESH_SUPPLEMENTAL_RECORD_UI |
9686 | IUPHAR_LIGAND_ID |
DB06083 | DRUGBANK_ID |
019085 | NDDF |
4041457 | VANDF |
C4541381 | UMLSCUI |
D11365 | KEGG_DRUG |
10253 | INN_ID |
6439522 | PUBCHEM_CID |
2602286 | RXNORM |
359272 | MMSL |
40699 | MMSL |
84HW7D0V04 | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
VTAMA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81672-5051 | CREAM | 10 mg | TOPICAL | NDA | 23 sections |